Oncology | Preclinical Developments

Onxeo

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

WRIB

Participation Not Confirmed

Update your events

Onxeo to Present Next-Generation PARP inhibitor, OX401, at the European ESMO-TAT Congress 2020

Lead Product(s): OX401

Therapeutic Area: Oncology

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 27, 2020

Details:

The data will showcase the high affinity with PARP that leads to DDR inhibition, metabolic exhaustion and activation of the innate immune response, specifically in tumoral cells.

Advanced BioDesign

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

WRIB

Participation Not Confirmed

Update your events

Advanced BioDesign Raises Additional €9 Million From Xerys Funds

Lead Product(s): ABD-3001

Therapeutic Area: Oncology

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Xerys Funds

Deal Size: $9.8 million Upfront Cash: Undisclosed

Deal Type: Funding February 26, 2020

Details:

Advanced BioDesign will finalise its preclinical studies and submit a clinical trial authorization to start clinical phase I in AML in early 2021.

Immatics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

WRIB

Participation Not Confirmed

Update your events

GSK pays $50M for 2 solid tumor cell therapies from Immatics

Lead Product(s): Allogeneic T-cell therapies

Therapeutic Area: Oncology

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: GlaxoSmithKline

Deal Size: $600.0 million Upfront Cash: $50.0 million

Deal Type: Collaboration February 20, 2020

Details:

GSK to obtain access to two Immatics TCR-T programs, further advancing their commitment to the field of cell therapies.

Novan

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

WRIB

Participation Not Confirmed

Update your events

Novan Receives Phase 2 NIH Federal Grant of $1.0 Million

Lead Product(s): WH602

Therapeutic Area: Oncology

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: National Institutes of Health

Deal Size: $1.7 million Upfront Cash: Undisclosed

Deal Type: Funding February 20, 2020

Details:

The grant will provide reimbursement for certain project expenses related to the advancement of WH602, a central focus of Novan’s women’s health business unit.

Mycenax Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

TAIWAN Taiwan

Post An Enquiry

Virtual Booth

WRIB

Participation Not Confirmed

Update your events

Hummingbird Bioscience Announces Agreement with Mycenax Biotech for Production of Anti-VISTA Antibody

Lead Product(s): HMBD-002

Therapeutic Area: Oncology

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Hummingbird Bioscience

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement February 20, 2020

Details:

Pre-clinical studies have shown that HMBD-002 can strongly inhibit tumor growth, both as a monotherapy and even more potently when combined with anti-PD(L)1 treatment.

TriSalus Life Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

WRIB

Participation Not Confirmed

Update your events

TriSalus Life Sciences Initiate Trial for Novel Delivery Technology

Lead Product(s): Oxaliplatin

Therapeutic Area: Oncology

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 12, 2020

Details:

Study to evaluate the Pressure-Enabled Drug Delivery™ approach combined with standard of care chemotherapy to enable deep tumor penetration and minimize dose-limiting toxicity.

WPD Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

POLAND Poland

Post An Enquiry

Virtual Booth

WRIB

Participation Not Confirmed

Update your events

WPD Pharma to Conduct Clinical Trials in Pediatric Brain Tumors

Lead Product(s): Berubicin

Therapeutic Area: Oncology

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 12, 2020

Details:

The Company, in collaboration with CNS, is planning to conduct the upcoming Phase I clinical trial at Children's Memorial Health Institute

Aptorum

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Hong Kong

Post An Enquiry

Virtual Booth

WRIB

Participation Not Confirmed

Update your events

Aptorum Group Announces Significant Progress of SACT-1

Lead Product(s): SACT-1

Therapeutic Area: Oncology

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 10, 2020

Details:

Subject to completion of current validation studies, Aptorum Group plans to leverage the 505(b)(2) pathway and submit an IND submission with the FDA for SACT-1 in H2 2020.